Peroxisome proliferator-activated receptors as stimulants of angiogenesis in cardiovascular disease and diabetes

Review

(2441) Views  (976) Full article downloads

Authors: Cyrus V Desouza, Lindsey Rentschler, Vivian Fonseca

Published Date September 2009 Volume 2009:2 Pages 165 - 172

DOI: http://dx.doi.org/10.2147/DMSO.S4170

Cyrus v Desouza^1,2, Lindsey Rentschler¹, Vivian Fonseca³

¹University of Nebraska Medical Center, ²Omaha VA Medical Center, Omaha, NE, USA; Scott & White Medical Clinic/Texas A & M College of Medicine, Temple, TX, USA

Abstract: The incidence of diabetes is directly related to the incidence of obesity, which is at epidemic proportions in the US. Cardiovascular disease is a common complication of diabetes, which results in high morbidity and mortality. Peroxisome proliferator-activated receptors (PPARs) are a group of nuclear hormone receptors that regulate lipid and glucose metabolism. PPAR-α agonists such as fenofibrate and PPAR-γ agonists such as the thiozolidinediones have been used to treat dyslipidemia and insulin resistance in diabetes. Over the past few years research has discovered the role of PPARs in the regulation of inflammation, proliferation, and angiogenesis. Clinical trials looking at the effect of PPAR agonists on cardiovascular outcomes have produced controversial results. Studies looking at angiogenesis and proliferation in various animal models and cell lines have shown a wide variation in results. This may be due to the differential effects of PPARs on proliferation and angiogenesis in various tissues and pathologic states. This review discusses the role of PPARs in stimulating angiogenesis. It also reviews the settings in which stimulation of angiogenesis may be either beneficial or harmful.

Keywords: PPAR, VEGF, angiogenesis, cardiovascular

Readers of this article also read: